Endo begins shipping generic Seroquel XR
DUBLIN — Endo announced Tuesday that Par Pharmaceutical had begun shipping its generic of Seroquel XR (quetiapine fumarate extended-release) tablets. Par will have 180 days of market exclusivity for the 50-, 100-, 150-, 200- and 300-mg dosage strength tablets.
The drug had U.S. sales of $911 million for the 12 months ended September 2016, according to QuintilesIMS data. Profits from Par’s generic will be shared with its partners Hand Pharmaceuticals and Deerfield Generics.
Allergan completes Tobira Therapeutics acquisition
DUBLIN — Allergan’s has completed its $1.7 billion acquisition of clinical-stage biopharma company Tobira Therapeutics, the company announced Tuesday. Tobira focuses on developing and commercializing treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases. Allergan paid $28.35 per share of the company, as well as contingent value rights, potentially payable upon completion of certain development, regulatory and commercial milestones.
"The completion of the acquisition of Tobira positions Allergan well in developing novel treatments for NASH, a disease set to become one of the next epidemic-level chronic diseases society faces," said David Nicholson, Chief R&D Officer, Allergan. "Both the CVC and Evogliptin programs provide highly differentiated compounds that can make a significant impact in the treatment of NASH, where today there are no approved therapies available for patients."
The acquisition of Tobira was announced the same day in September as Allergan’s planned acquisition of another company focused on developing treatments for NASH. The Tobira acquisition adds two development programs, Cenicriviroc and Evogloptin to Allergan’s global gastroenterology research and development pipeline.
In April, Drug Store News spoke to Diplomat Pharmacy emerging therapeutics analyst Ryan Chandanais, who said that NASH — a type of fatty liver disease whose fat accumulation is accompanied by inflammation and cellular damage — is a disease state whose lack of approved treatment is garnering drugmakers’s attention.
Camber launches generic Crestor
PISCATAWAY, N.J. — Camber Pharmaceuticals on Monday announced the launch of its Crestor (rosuvastatin) generic. The drug is indicated to treat high triglycerides and cholesterol.
Crestor had U.S. moving annual total sales of $6.43 billion for the 12 months ended May 2016, according to IMS Health data. Camber’s generic will be available in 90-count bottles of 5-, 10- and 20-mg dosage strengths, and 30-count bottles of 40-mg dosage strength.
Loading Post Please Wait...